Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Brepocitinib Modified Release Formulations in Healthy Participants
NCT04580797Phase 1Completed
- Sponsor
- Pfizer
- Start
- Oct 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of brepocitinib in plaque psoriasis, psoriatic arthritis (PsA), systemic lupus erythematosus (SLE) and 4 more (9 arms), sponsored by Pfizer. Primary endpoints: Maximum Observed Plasma Concentration, Area under the plasma concentration-time curve from time zero to the last measured concentration and 3 more. Started Oct 2020; status: completed.
02
Drugs
brepocitinib
03
Conditions
plaque psoriasispsoriatic arthritis (PsA)systemic lupus erythematosus (SLE)dermatomyositis (DM)ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04580797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04580797.